Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Veeva Systems (VEEV) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal second-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Here's Why You Should Retain Cardinal Health Stock for Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.

Allscripts' Collaboration to Advance Healthcare Innovation

by Zacks Equity Research

Allscripts (MDRX) partners with Israel's Sheba Medical Center to help enhance healthcare innovation with smarter technology, thereby improving patient outcomes.

PerkinElmer's Hand Sanitizer Analyzer to Test for Methanol

by Zacks Equity Research

PerkinElmer's (PKI) Hand Sanitizer Analyzer can help lab professionals and scientists all over the world in their fight against COVID-19.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.

Ecolab's Synergex Sanitizer & Disinfectant Gets First EPA Nod

by Zacks Equity Research

Ecolab's (ECL) Synergex Santizer & Disinfectant becomes the first product to receive U.S. EPA for efficacy against biofilms.

Urmimala Biswas headshot

Will Thermo Fisher's (TMO) Failed QIAGEN Deal Cost it a Lot?

by Urmimala Biswas

The COVID-19 tailwinds are significantly stronger than what Thermo Fisher (TMO) had originally expected in March.

McKesson Extends Partnership With CDC to Fight Coronavirus

by Zacks Equity Research

McKesson (MCK) extends partnership with the CDC to aid in the distribution of future COVID-19 vaccines.

PerkinElmer Launches Workstations for Coronavirus Testing

by Zacks Equity Research

PerkinElmer's (PKI) scalable and modular explorer automated workstations simplify testing workflows, thereby expediting the process of SARS-CoV-2 RT-PCR testing.

Swayta Shah headshot

Add These 5 Stocks With Solid Sales Growth to Your Portfolio

by Swayta Shah

Sales growth is an important metric for any company, as it is vital part of growth projections and is instrumental in strategic decision making.

Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness

by Zacks Equity Research

The FDA approval of Masimo's (MASI) PVi system will enable patient safety.

Here's Why You Should Hold on to Intuitive Surgical Stock Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.

Baxter (BAX) Receives EUA for Regiocit Replacement Solution

by Zacks Equity Research

Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.

Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated

by Zacks Equity Research

Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.

Here's Why You Should Hold on to Stryker (SYK) Stock Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates

by Zacks Equity Research

Accuray (ARAY) registered decline in Product and Service revenues in Q4

Medtronic (MDT) Plans $160 Million R&D Investment in India

by Zacks Equity Research

The newest expansion plan of MEIC will help Medtronic (MDT) advance in the field of pain alleviation and restoration of health.

HMS Holdings (HMSY) Loses 2.9% Since Q2 Earnings Release

by Zacks Equity Research

HMS Holdings (HMSY) witnessed revenue growth in COB segment in Q2.

Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across the Network Solutions segment and lower operating expenses.

Has PerkinElmer (PKI) Outpaced Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Is (PKI) Outperforming Other Computer and Technology Stocks This Year?

Chemed's (CHE) VITAS Business Strong Amid Coronavirus Crisis

by Zacks Equity Research

Amid the pandemic scenario, Chemed's (CHE) VITAS and Roto-Rooter both have been classified as essential services.

AMN Healthcare (AMN) Loses 3.3% Despite Q2 Earnings Beat

by Zacks Equity Research

AMN Healthcare (AMN) gained from two of its three core operating segments in Q2.

Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat

by Zacks Equity Research

Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

PRA Health (PRAH) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PRA Health's (PRAH) Data Solutions segment puts up a strong performance in Q2.

Surmodics (SRDX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.